Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab
Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...
Biogen
Biogen’s Aducanumab Administered to Chinese Patient for First Time
US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a...
Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China
The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...